Toll receptors modulate allergic responses: Interaction with dendritic cells, T cells and mast cells

Current Opinion in Allergy and Clinical Immunology

Volumn 3, Issue 6, 2003, Pages 487-494

  Bellou, Abdelouahab ^a   Schaub, Bianca ^a   Ting, Leon ^a   Finn, Patricia W ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Allergy; Dendritic cells; Mast cells; T regulatory cells; Toll like receptor

Indexed keywords

CD4 ANTIGEN; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; CELL SURFACE RECEPTOR; MEMBRANE PROTEIN;

ALLERGY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CELL FUNCTION; CELL INTERACTION; CELL MATURATION; CELL TYPE; CELLULAR DISTRIBUTION; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOREGULATION; LYMPHOCYTE DIFFERENTIATION; MAST CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

DENDRITIC CELLS; HUMANS; HYPERSENSITIVITY; MAST CELLS; MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 3543085777     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200312000-00011     Document Type: Review

References (118)

1. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989; 54:1-13.
2. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20:197-216.
3. Barton GM, Medzhitov R. Control of adaptive immune responses by Toll-like receptors. Curr Opin Immunol 2002; 14:380-383.
4. Vogel SN, Fenton M. Toll-like receptor 4 signalling: new perspectives on a complex signal-transduction problem. Biochem Soc Trans 2003; 31:664-668. This review gives information about the recent controversy on the role of Toll/IL-1 domain-containing adapter protein/MyD88-adapter-like in TLR2 and TLR4 signaling, The findings provide the mechanistic basis for differential patterns of gene expression activated by TLR4 and TLR2 agonists.
5. O'Neill LA. The role of MyD88-like adapters in Toll-like receptor signal transduction. Biochem Soc Trans 2003; 31:643-647.
6. Barton GM, Medzhitov R. Toll-like receptors and their ligands. Curr Top Microbiol Immunol 2002; 270:81-92.
7. Sabroe I, Prince LR, Jones EC, et al. Selective roles for Toll-like receptor (TLR)2 and TLR4 in the regulation of neutrophil activation and life span. J Immunol 2003; 170:5268-5275. This review summarizes and discusses recent studies focusing on the role of TLR signaling in allergic and non-allergic inflammatory diseases. The involvement of this signaling in gene transcription processes is important in immunostimulatory and immunomodulatory effects.
8. Raby BA, Klimecki WT, Laprise C, et al. Polymorphisms in toll-like receptor 4 are not associated with asthma or atopy-related phenotypes. Am J Respir Crit Care Med 2002; 166:1449-1456.
9. Lazarus R, Vercelli D, Palmer LJ, et al. Single nucleotide polymorphisms in innate immunity genes: abundant variation and potential role in complex human disease. Immunol Rev 2002; 190:9-25.
10. Werner M, Topp R, Wimmer K, et al. TLR4 gene variants modify endotoxin effects on asthma. J Allergy Clin Immunol 2003; 112:323-330.
11. Brawand P, Fitzpatrick DR, Greenfield BW, et al. Murine plasmacytoid predendritic cells generated from Flt3 ligand-supplemented bone marrow cultures are immature APCs. J Immunol 2002; 169:6711-6719.
12. Huang FP, Platt N, Wykes M, et al. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med 2000; 191:435-444.
13. Liu YJ, Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001; 106:259-262.
14. Banchereau J, Paczesny S, Blanco P, et al. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann NY Acad Sci 2003; 987:180-187.
15. Rissoan MC, Soumelis V, Kadowaki N, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283:183-186.
16. Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat Immunol 2000; 1:199-205.
17. Langenkamp A, Messi M, Lanzavecchia A, et al. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 2000; 1:311-316.
18. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003; 299:1033-1036. This important study examines the interaction between the TLR pathway with T regulatory cells via the activation of dendritic cells. The stimulation of TLR induces the production of IL-6, which in turn blocks the activation of T regulatory cells allowing activation of pathogen-specific adaptive immune responses. This blockade could thus prevent chronic infection and autoimmune diseases.
19. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001; 2:816-822,
20. Whelan M, Harnett MM, Houston KM, et al. A filarial nematode-secreted product signals dendritic cells to acquire a phenotype that drives development of Th2 cells. J Immunol 2000; 164:6453-6460.
21. MacDonald AS, Straw AD, Bauman B, et al. CD8-dendritic cell activation status plays an integral role in influencing Th2 response development. J Immunol 2001; 167:1982-1988.
22. Ochoa MT, Legaspi AJ, Hatziris Z, et al. Distribution of Toll-like receptor 1 and Toll-like receptor 2 in human lymphoid tissue. Immunology 2003; 108:10-15.
23. Pulendran B, Kumar P, Cutler CW, et al. Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J Immunol 2001; 167:5067-5076.
24. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194:863-869.
25. Jarrossay D, Napolitani G, Colonna M, et al. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 2001; 31:3388-3393.
26. Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001; 31:3026-3037.
27. Schnare M, Barton GM, Holt AC, et al. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001; 2:947-950.
28. Kaisho T, Hoshino K, Iwabe T, et al. Endotoxin can induce MyD88-deficient dendritic cells to support T(h)2 cell differentiation. Int Immunol 2002; 14:695-700. This study demonstrates that MyD88-deficient dendritic cells can prime naive T lymphocytes towards Th2 responses. MyD88 seems not to be involved in the modulation of the Th1/Th2 balance. A MyD88 independent pathway may play a role in allergic immune responses.
29. Dabbagh K, Dahl ME, Stepick-Biek P, et al. Toll-like receptor 4 is required for optimal development of Th2 immune responses: role of dendritic cells. J Immunol 2002; 168:4524-4530. This study shows a decrease of Th2 responses in TLR4-deficient mice sensitized to inhaled allergen. The expression of co-stimulatory molecules and cytokine production are decreased in TLR4-deficient dendritic cells and may explain the Th2 priming impairment.
30. Eisenbarth SC, Piggott DA, Huleatt JW, et al. Lipopolysaccharide- enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 2002; 196:1645-1651. This study demonstrates that TLR4 signalling may be critical in Th2 immune responses. Low-dose inhaled lipopolysaccharide combined with allergen induces Th2 responses, whereas high-dose lipopolysaccharide resulted in Th1 responses.
31. Re F, Strominger JL. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 2001; 276:37692-37699.
32. Dabbagh K, Lewis DB. Toll-like receptors and T-helper-1/T-helper-2 responses. Curr Opin Infect Dis 2003; 16:199-204. This review discusses the recent studies demonstrating the role of TLR in the modulation and regulation of Th1 and Th2 immune adaptive responses, The authors focus on the controversial role of TLRs in Th2 responses with an increase in dendritic cell maturation. A better understanding of this pathway could be helpful to develop preventative treatment of allergic diseases.
33. Ruedl C, Bachmann MF, Kopf M. The antigen dose determines T helper subset development by regulation of CD40 ligand. Eur J Immunol 2000; 30:2056-2064.
34. Tanaka H, Demeure CE, Rubio M, et al. Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or Th1/ Th2 effectors. Role of stimulator/responder ratio. J Exp Med 2000; 192:405-412.
35. Vannier E, Lefort J, Lellouch-Tubiana A, et al. Lipopolysaccharide from Escherichia coli reduces antigen-induced bronchoconstriction in actively sensitized guinea pigs. J Clin Invest 1991; 87:1936-1944.
36. Tulic MK, Wale JL, Holt PG, et al. Modification of the inflammatory response to allergen challenge after exposure to bacterial lipopolysaccharide. Am J Respir Cell Mol Biol 2000; 22:604-612.
37. Herrick CA, MacLeod H, Glusac E, et al. Th2 responses induced by epicutaneous or inhalational protein exposure are differentially dependent on IL-4. J Clin Invest 2000; 105:765-775.
38. Wan GH, Li CS, Lin RH. Airborne endotoxin exposure and the development of airway antigen-specific allergic responses. Clin Exp Allergy 2000; 30:426-432.
39. Heinzel FP, Rerko RM, Ling P, et al. Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of gamma interferon. Infect Immun 1994; 62:4244-4249.
40. Keane-Myers A, Wysocka M, Trinchieri G, et al. Resistance to antigen-induced airway hyperresponsiveness requires endogenous production of IL-12. J Immunol 1998; 161:919-926.
41. Park JH, Gold DR, Spiegelman DL, et al. House dust endotoxin and wheeze in the first year of life. Am J Respir Crit Care Med 2001; 163:322-328.
42. Gereda JE, Leung DY, Thatayatikom A, et al. Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitisation in infants at high risk of asthma. Lancet 2000; 355:1680-1683.
43. Liu AH. Endotoxin exposure in allergy and asthma: reconciling a paradox. J Allergy Clin Immunol 2002; 109:379-392.
44. Erb KJ, Atopic disorders: a default pathway in the absence of infection? Immunol Today 1999; 20:317-322.
45. Cohn L, Tepper JS, Bottomly K. IL-4-independent induction of airway hyperresponsiveness by Th2, but not Th1, cells. J Immunol 1998; 161:3813-3816.
46. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326:298-304.
47. Alm JS, Swartz J, Lilja G, et al. Atopy in children of families with an anthroposophic lifestyle. Lancet 1999; 353:1485-1488.
48. Shaheen SO, Aaby P, Hall AJ, et al. Measles and atopy in Guinea-Bissau. Lancet 1996; 347:1792-1796.
49. Shirakawa T, Enomoto T, Shimazu S, et al. The inverse association between tuberculin responses and atopic disorder. Science 1997; 275:77-79.
50. von Hertzen LC, Haahtela T. Could the risk of asthma and atopy be reduced by a vaccine that induces a strong T-helper type 1 response? Am J Respir Cell Mol Biol 2000; 22:139-142.
51. von Hertzen LC. Puzzling associations between childhood infections and the later occurrence of asthma and atopy. Ann Med 2000; 32:397-400.
52. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998; 351:1225-1232.
53. Platts-Mills TA, Woodfolk JA, Sporik RB. Con: the increase in asthma cannot be ascribed to cleanliness. Am J Respir Crit Care Med 2001; 164:1107-1108; discussion 1108-1109.
54. von Mutius E. Pro: the increase in asthma can be ascribed to cleanliness. Am J Respir Crit Care Med 2001; 164:1106-1107; discussion 1108-1109.
55. Onkamo P, Vaananen S, Karvonen M, et al. Worldwide increase in incidence of type I diabetes - the analysis of the data on published incidence trends. Diabetologia 1999; 42:1395-1403.
56. Fonager K, Sorensen HT, Olsen J. Change in incidence of Crohn's disease and ulcerative colitis in Denmark. A study based on the National Registry of Patients, 1981-1992. Int J Epidemiol 1997; 26:1003-1008.
57. Yazdanbakhsh M, van den Biggelaar A, Maizels RM. Th2 responses without atopy: immunoregulation in chronic helminth infections and reduced allergic disease. Trends Immunol 2001; 22:372-377.
58. van den Biggelaar AH, Lopuhaa C, van Ree R, et al. The prevalence of parasite infestation and house dust mite sensitization in Gabonese school-children. Int Arch Allergy Immunol 2001; 126:231-238.
59. Tulic MK, Manoukian JJ, Eidelman DH, et al. T-cell proliferation induced by local application of LPS in the nasal mucosa of nonatopic children. J Allergy Clin Immunol 2002; 110:771-776. This paper underscores the importance of lipopolysaccharide exposure in early life inducing a shift of the immune phenotype towards a Th1 pattern.
60. Bellinghausen I, Klostermann B, Knop J, et al. Human CD4+CD25+ T cells derived from the majority of atopic donors are able to suppress TH1 and TH2 cytokine production. J Allergy Clin Immunol 2003; 111:862-868. This study reports evidence that CD4+CD25+ T regulatory cells are present and functional in most atopic patients and are capable of inhibiting Th1 as well as Th2 cytokine production.
61. Belkaid Y, Piccirillo CA, Mendez S, et al. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 2002; 420:502-507. The authors show that CD4+ CD25+ T cells control Leishmania major persistence and immunity in a murine model.
62. Caramalho I, Lopes-Carvalho T, Ostler D, et al. Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003; 197:403-411. This important study demonstrates for the first time that T regulatory cells express TLRs. T regulatory cells activated by microbial products contribute to the control of inflammation, and potentially regulate allergic responses.
63. Schjetne KW, Thompson KM, Nilsen N, et al. Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target. J Immunol 2003; 171:32-36.
64. van den Biggelaar AH, van Ree R, Rodrigues LC, et al. Decreased atopy in children infected with Schistosoma haematobium: a role for parasite-induced interleukin-10. Lancet 2000; 356:1723-1727.
65. Powrie F, Maloy KJ. Immunology. Regulating the regulators. Science 2003; 299:1030-1031.
66. Zuany-Amorim C, Sawicka E, Manlius C, et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med 2002; 8:625-629. This paper shows that previous exposure to microbial antigens can suppress the subsequent generation of an antigen-specific airway inflammatory response and decrease Th2 responses.
67. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2:389-400. This recent review focuses on the complex function of CD4+CD25+ suppressor T cells as powerful inhibitors in T-cell activation. Enhancement of these cells may result in the prevention of allergic diseases.
68. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-712.
69. Athanassakis I, Vassiliadis S. T-regulatory cells: are we re-discovering T suppressors? Immunol Lett 2002; 84:179-183.
70. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1:135-145.
71. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:330-336.
72. Tulic MK, Knight DA, Holt PG, et al. Lipopolysaccharide inhibits the late-phase response to allergen by altering nitric oxide synthase activity and interleukin-10. Am J Respir Cell Mol Biol 2001; 24:640-646.
73. Prescott SL, Macaubas C, Smallacombe T, et al. Development of allergen-specific T-cell memory in atopic and normal children. Lancet 1999; 353:196-200.
74. Devereux G, Seaton A, Barker RN. In utero priming of allergen-specific helper T cells. Clin Exp Allergy 2001; 31:1686-1695.
75. Devereux G, Barker RN, Seaton A. Antenatal determinants of neonatal immune responses to allergens. Clin Exp Allergy 2002; 32:43-50.
76. Braun-Fahrlander C. The role of the farm environment and animal contact for the development of asthma and allergies. Clin Exp Allergy 2001; 31:1799-1803.
77. Braun-Fahrlander C, Riedler J, et al. Current exposure to endotoxin in mattress dust is inversely related to hay fever, atopy and atopic asthma in school children from rural areas [abstract]. Am J Respir Crit Care Med 2002; 165 (Suppl 8):A679.
78. Braun-Fahrlander C, Lauener R. Farming and protective agents against allergy and asthma. Clin Exp Allergy 2003; 33:409-411.
79. Braun-Fahrlander C, Riedler J, Herz U, et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 2002; 347:869-877. This important study supports evidence that increased endotoxin levels in the domestic environment are inversely related to the occurrence of allergic diseases in a rural population of children.
80. Northridge ME, Meyer IH, Dunn L. Overlooked and underserved in Harlem: a population-based survey of adults with asthma. Environ Health Perspect 2002; 110 (Suppl. 2):217-220.
81. Perera FP, Illman SM, Kinney PL, et al. The challenge of preventing environmentally related disease in young children: community-based research in New York City. Environ Health Perspect 2002; 110:197-204.
82. Lauener RP, Birchler T, Adamski J, et al. Expression of CD14 and Toll-like receptor 2 in farmers' and non-farmers' children. Lancet 2002; 360:465-466. This study shows higher amounts of CD14 and TLR2 in a population of farmers' children, who grow up in an endotoxin-rich environment and have a lower incidence of asthma. These results emphasize that TLR2 stimulation may prevent allergic diseases.
83. van der Kleij D, Latz E, Brouwers JF, et al. A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization. J Biol Chem 2002; 277:48122-48129. This study is the first to show an interaction between TLR2 and parasites. The authors demonstrate that the molecule phosphatidylserine of schistosomes can activate TLR2 and induce dendritic cell maturation and IL-10-producing T regulatory cells.
84. Yazdanbakhsh M, Kremsner PG, van Ree R. Allergy, parasites, and the hygiene hypothesis. Science 2002; 296:490-494.
85. Hussain R, Poindexter RW, Ottesen EA. Control of allergic reactivity in human filariasis. Predominant localization of blocking antibody to the IgG4 subclass. J Immunol 1992; 148:2731-2737.
86. Prussin C, Metcalfe DD. 4th part of a report. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003; 111(2 Suppl):S486-S494.
87. Malaviya R, Ikeda T, Ross E, et al. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 1996; 381:77-80.
88. Echtenacher B, Mannel DN, Hultner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996; 381:75-77.
89. Supajatura V, Ushio H, Nakao A, et al. Protective roles of mast cells against enterobacterial infection are mediated by Toll-like receptor 4. J Immunol 2001; 167:2250-2256.
90. McCurdy JD, Lin TJ, Marshall JS. Toll-like receptor 4-mediated activation of murine mast cells. J Leukoc Biol 2001; 70:977-984.
91. Supajatura V, Ushio H, Nakao A, et al. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest 2002; 109:1351-1359. This study reports that stimulation of mast cells with the TLR2 ligand, peptidoglycan, and the TLR4 ligand, lipopolysaccharide, produces differential responses from mast cells in terms of cytokine production and degranulation.
92. Masuda A, Yoshikai Y, Aiba K, et al. Th2 cytokine production from mast cells is directly induced by lipopolysaccharide and distinctly regulated by c-Jun N-terminal kinase and p38 pathways. J Immunol 2002; 169:3801-3810. The authors show that lipopolysaccharide induced Th2-associated cytokine production that was synergistically enhanced with IgE cross-linking.
93. McCurdy JD, Olynych TJ, Maher LH, et al. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J Immunol 2003; 170:1625-1629. The authors show that human mast cells express TLR1, TLR2 and TLR6, but not TLR4. They also show that mast cells do not respond to lipopolysaccharide, and have differential responses to various TLR2 ligands.
94. Varadaradjalou S, Feger F, Thieblemont N, et al. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol 2003; 33:899-906. This study reports that human mast cells require priming by IL-4 and soluble CD14 cells in order to be responsive to lipopolysaccharide. They also show that activation of the TLR2 or TLR4 pathway may lead to a pro-Th2 immune response.
95. Mita Y, Dobashi K, Endou K, et al. Toll-like receptor 4 surface expression on human monocytes and B cells is modulated by IL-2 and IL-4. Immunol Lett 2002; 81:71-75.
96. Marteau P, Seksik P, Jian R. Probiotics and health: new facts and ideas. Curr Opin Biotechnol 2002; 13:486-489.
97. Kalliomaki M, Salminen S, Arvilommi H, et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357:1076-1079.
98. Rautava S, Kalliomaki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002; 109:119-121. This study demonstrates the immunomodulatory effect of probiotics in allergic diseases. The administration of probiotics during pregnancy and breast-feeding may promote the immunoprotective potential of breast-feeding and provide protection against atopic eczema during the first 2 years of life.
99. Rachmilewitz D, Karmeli F, Takabayashi K, et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 2002; 122:1428-1441. This recent study demonstrates that immunostimulatory sequences also known as CpG motifs prevent and ameliorate dextran sodium sulfate and hapten-induced colitis, with an improvement of clinical, biochemical and histological scores in colonic inflammation. The immunostimulatory DNA could be useful in the treatment of human inflammatory bowel disease.
100. Krieg AM. The role of CpG motifs in innate immunity. Curr Opin Immunol 2000; 12:35-43.
101. Wild JS, Sur S. CpG oligonucleotide modulation of allergic inflammation. Allergy 2001; 6:365-376.
102. Madsen K, Jijon H, Yeung H, et al. DNA from probiotic bacteria exerts antiinflammatory actions on epithelial cells by inhibition of NF-kB [abstract]. Gastroenterology 2002; 122:546.
103. Sur S, Wild JS, Choudhury BK, et al. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol 1999; 162:6284-6293.
104. Kline JN, Kitagaki K, Businga TR, et al. Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. Am J Physiol Lung Cell Mol Physiol 2002; 283:L170-L179. This important study demonstrates that CpG oligodeoxynucleotides may improve established asthma in a murine model. CpG oligodeoxynucleotides combined with allergen can reverse eosinophilic airways by redirecting Th2 responses towards Th1 responses.
105. Shirota H, Sano K, Kikuchi T, et al. Regulation of T-helper type 2 cell and airway eosinophilia by transmucosal coadministration of antigen and oligodeoxynucleotides containing CpG motifs. Am J Respir Cell Mol Biol 2000; 22:176-182.
106. Kitagaki K, Jain VV, Businga TR, et al. Immunomodulatory effects of CpG oligodeoxynucleotides on established th2 responses. Clin Diagn Lab Immunol 2002; 9:1260-1269. This paper suggests that CpG oligodeoxynucleotides may inhibit Th2 responses through IFN-γ and IL-10 production, which regulate excessive Th1 responses.
107. Zuany-Amorim C, Haile S, Leduc D, et al. Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice. J Clin Invest 1995; 95:2644-2651.
108. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3:196-200. This important paper demonstrates that the activation of immune cells by imidazoquinoline is induced through the MyD88-dependent pathway via TLR7 and induces an antiviral effect. Compared with other TLR ligands, imidazoquinolines are potent inducers of IFN-γ secretion.
109. Jurk M, Heil F, Vollmer J, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002; 3:499.
110. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002; 27:571-577.
111. Rhodes J. Discovery of immunopotentiatory drugs: current and future strategies. Clin Exp Immunol 2002; 130:363-369.
112. Tsuji RF, Hoshino K, Noro Y, et al. Suppression of allergic reaction by lambda-carrageenan: toll-like receptor 4/MyD88-dependent and -independent modulation of immunity. Clin Exp Allergy 2003; 33:249-258. This study shows for the first time that non-microbial molecules can act on TLRs. Oral administration of λ-carrageenan to immunized mice decreases OVA (ovalbumin)-specific IgE and is also effective in previously immunized mice. This effect is dependent on a TLR4 and MyD88 pathway with increased IFN-γ and decreased IL-4.
113. Bach JF. Protective role of infections and vaccinations on autoimmune diseases. J Autoimmun 2001; 16:347-353.
114. Hansen G, Berry G, DeKruyff RH, et al. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J Clin Invest 1999; 103:175-183.
115. Randolph DA, Stephens R, Carruthers CJ, et al. Cooperation between Th1 and Th2 cells in a murine model of eosinophilic airway inflammation. J Clin Invest 1999; 104:1021-1029.
116. Wild JS, Sigounas A, Sur N, et al. IFN-gamma-inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines, and airway eosinophilia in a mouse model of allergic asthma. J Immunol 2000; 164:2701-2710.
117. Herrick CA, Bottomly K. To respond or not to respond: T cells in allergic asthma. Nat Rev Immunol 2003; 3:405-412.
118. Coutinho A, Hori S, Carvalho T, et al. Regulatory T cells: the physiology of autoreactivity in dominant tolerance and 'quality control' of immune responses. Immunol Rev 2001; 182:89-98.